Biocon’s Kiran Mazumdar-Shaw says move won’t hurt Indian pharma exports, could boost contract research
Pharmaceutical firm Dr Reddy's Laboratories announced its quarterly results for the March 2024 quarter on Friday. The company reported a 22% year-on-year rise in consolidated net profit, reaching Rs 1...
By linking US drug prices to those paid in similar economies, order could alter how pharmaceutical companies price their products in the US, potentially affecting operations of Indian companies in thi...
Company positioning India as key hub for future ophthalmic innovation and access in Asia-Pacific region.
Union Minister of State for Science and Technology, Jitendra Singh, said earlier test missions have prepared the ground for the upcoming phases.
Small town India is turning out to be a powerful magnet for organised diagnostic players. they are contributing a significant part of revenues, outpacing metros in growth. Will the ride continue?
Interor, a European player in pharmaceutical intermediates and specialty chemicals, is eyeing India for its next phase of growth. CEO Geoffroy Waroqueaux shares insights on potential investment, partn...
The US is considering a 25% tariff on imported pharmaceuticals, including APIs and finished drugs — a move that could seriously impact Indian drugmakers. India, which holds the second-highest numbe...
Company focusing on collaborations rather than direct investment in manufacturing or research and development facilities in India.
The investment will cover both greenfield and brownfield projects, with ₹350–400 crore already deployed, the company told Business Today
Mark Mobius: U.S.-India Trade Deal Is 'Very Significant' for Investor Confidence
How Masood Azhar And Jaish-e-Mohammed Orchestrated Some Of India’s Bloodiest Terror Attacks
Mark Mobius: US-China Trade War Not Over Yet, Non-Tariff Barriers Still A Concern
How To Navigate Markets Post India- Pakistan Tensions & What Triggers To Watch Out For At This Time
Mark Mobius Reveals Top Sectors For Investment: Innovation, Tech, And More
